Current and Emerging Treatment Options in Pediatric Onset Multiple Sclerosis
Open Access
Abstract
Pediatric onset multiple sclerosis (POMS), characterized by the onset of multiple sclerosis before the age of 18, is gaining increased recognition. Approximately 5 percent of MS cases manifest before the age of 18, with less than 1 percent occurring before the age of 10. Despite its rarity, pediatric MS exhibits distinct characteristics, with an association between younger age at onset and a comparatively slower disease progression. Despite this slower progression, individuals with POMS historically reach disability milestones at earlier ages than those with adult-onset multiple sclerosis. While various immunomodulatory agents demonstrate significant benefits in MS treatment, such as reduced relapse rates and slower accumulation of brain lesions on magnetic resonance imaging (MRI), the majority of disease-modifying therapies (DMTs) commonly used in adult MS lack evaluation through pediatric clinical trials. Current evidence is predominantly derived from observational studies. This comprehensive review aims to consolidate existing knowledge on the mechanisms of action, efficacy, safety profiles, and recommended dosages of available DMTs specifically in the context of pediatric MS. Furthermore, this review outlines recent advancements and explores potential medications still in developmental stages, providing a thorough overview of the current landscape and future prospects for treating POMS.Keywords
All Related Versions
This publication has 144 references indexed in Scilit:
- Risk of Persistent Disability in Patients With Pediatric-Onset Multiple SclerosisJAMA Neurology, 2021
- Association Between Cigarette Smoking and Multiple SclerosisJAMA Neurology, 2020
- Teriflunomide for multiple sclerosisCochrane Database of Systematic Reviews, 2016
- Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple SclerosisArchives of Neurology, 2012
- Daclizumab Use in Patients With Pediatric Multiple SclerosisArchives of Neurology, 2012
- Glatiramer acetate for multiple sclerosisCochrane Database of Systematic Reviews, 2010
- Vitamin D status is associated with relapse rate in pediatric‐onset multiple sclerosisAnnals of Neurology, 2010
- Difference in Disease Burden and Activity in Pediatric Patients on Brain Magnetic Resonance Imaging at Time of Multiple Sclerosis Onset vs AdultsArchives of Neurology, 2009
- Increased Relapse Rate in Pediatric-Onset Compared With Adult-Onset Multiple SclerosisArchives of Neurology, 2009
- Azathioprine for multiple sclerosisCochrane Database of Systematic Reviews, 2007